News

Watson has posted a net income of $25.7m for the third quarter 2010, or $0.21 per diluted share, compared to net income of $63m, or $0.55 per diluted

In the trial, people participated lived a median of 6.2 months without their disease getting worse (median progression-free survival or PFS). Almost 52% of patients in the trial

In addition to the technical and business advisory services, the funding will be used to conduct studies and determine efficacy, selectivity and pharmacokinetics properties for the development of

Cymbalta has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. Cymbalta, which has been shown to reduce chronic low

The biological effects of SoftWave therapy include increased permeability of cell membranes, increased blood flow through angiogenesis, up-regulation of growth factors, and stem cell activation, and also proved

AVP-21D9 is presently in a randomised, double-blind, placebo-controlled, dose escalation Phase I clinical study involving 50 healthy volunteers designed to evaluate the safety and pharmacokinetics of the product

The funding will allow Achillion Pharmaceuticals to further advance its portfolio of HCV clinical candidates, as well as allow it to capitalise certain antibacterial assets. Achillion senior vice

The grants were awarded in recognition of its two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon(R) adjuvant. Antigenics

Bromodeoxyuridine (BrdU) – an analog of the DNA base thymidine – is a reagent commonly used in the detection of proliferating cells in living tissues and tissue samples.